Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 887736

The efficacy and safety of valsartan and combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension - the VICTORY trial


Accetto, Rok; Yevgenyevna Chazova, Irina; Sirenko, Yuriy; Vincelj, Josip; Widimsky Jr, Jiri; Barbič- Žagar, Breda
The efficacy and safety of valsartan and combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension - the VICTORY trial // Kardiologia Polska, 75 (2017), 1; 55-64 doi:10.5603/KP.a2016.0135 (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 887736 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
The efficacy and safety of valsartan and combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension - the VICTORY trial

Autori
Accetto, Rok ; Yevgenyevna Chazova, Irina ; Sirenko, Yuriy ; Vincelj, Josip ; Widimsky Jr, Jiri ; Barbič- Žagar, Breda

Izvornik
Kardiologia Polska (0022-9032) 75 (2017), 1; 55-64

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
arterial hypertension ; fixed-dose combination ; valsartan

Sažetak
The aim of the trial was to establish the efficacy and safety of Valsacor (valsartan) and Valsacombi(combination of valsartan and hydrochlorotiazide) in a wide variety of patients populations with midl to moderate arterial hypertension. We performed an international, multicentre, open-label, prospective trial. After one week of washout in previously treated patients, the patients were treated for 16 weeks according to the protocol. Naive patients entered the treatment period immediately. During the active treatment, four visits were planned for each patients to obtain the data for the primary and secondary efficacy endpoints analysis. The pricipal methods were blood pressure (BP) measurement, additionally in a subgroup of patients, assessment of erectile function. The initial dosage of valsartan 80 mg/day was titrated up to 320 mg/day to achieve the BP goal, with the addition of hydrochlorothiazide (HTZ) in a fixed- combination (FDC), if needed. Mean +/- standard deviation changes from baseline at week 16 were -26.6 +/- 10.4 mm Hg (systolic BP) and -14.8 +/- 7.6 mm Hg (diastolic BP). A total of 91% of the patients treated with either valsartan or valsartan FDC achieved the BP goal. Adverse reactions were experienced by 7.1% of the patients, with the most common being headache (1.9%), palpitation (1.6%), dizzines (1.6%) and fatigue (1.6%), during the whole trial. The results of the VICTORY trial show that valsartan and valsartan FDC effectively reduce the BP in patients with mild to moderate arterial hypertension and have a good tolerability profile.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Ustanove:
Klinička bolnica "Dubrava",
Zdravstveno veleučilište, Zagreb,
Medicinski fakultet, Osijek,
Sveučilište J. J. Strossmayera u Osijeku

Profili:

Avatar Url Josip Vincelj (autor)

Poveznice na cjeloviti tekst rada:

doi

Citiraj ovu publikaciju:

Accetto, Rok; Yevgenyevna Chazova, Irina; Sirenko, Yuriy; Vincelj, Josip; Widimsky Jr, Jiri; Barbič- Žagar, Breda
The efficacy and safety of valsartan and combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension - the VICTORY trial // Kardiologia Polska, 75 (2017), 1; 55-64 doi:10.5603/KP.a2016.0135 (međunarodna recenzija, članak, znanstveni)
Accetto, R., Yevgenyevna Chazova, I., Sirenko, Y., Vincelj, J., Widimsky Jr, J. & Barbič- Žagar, B. (2017) The efficacy and safety of valsartan and combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension - the VICTORY trial. Kardiologia Polska, 75 (1), 55-64 doi:10.5603/KP.a2016.0135.
@article{article, author = {Accetto, Rok and Yevgenyevna Chazova, Irina and Sirenko, Yuriy and Vincelj, Josip and Widimsky Jr, Jiri and Barbi\v{c}- \v{Z}agar, Breda}, year = {2017}, pages = {55-64}, DOI = {10.5603/KP.a2016.0135}, keywords = {arterial hypertension, fixed-dose combination, valsartan}, journal = {Kardiologia Polska}, doi = {10.5603/KP.a2016.0135}, volume = {75}, number = {1}, issn = {0022-9032}, title = {The efficacy and safety of valsartan and combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension - the VICTORY trial}, keyword = {arterial hypertension, fixed-dose combination, valsartan} }
@article{article, author = {Accetto, Rok and Yevgenyevna Chazova, Irina and Sirenko, Yuriy and Vincelj, Josip and Widimsky Jr, Jiri and Barbi\v{c}- \v{Z}agar, Breda}, year = {2017}, pages = {55-64}, DOI = {10.5603/KP.a2016.0135}, keywords = {arterial hypertension, fixed-dose combination, valsartan}, journal = {Kardiologia Polska}, doi = {10.5603/KP.a2016.0135}, volume = {75}, number = {1}, issn = {0022-9032}, title = {The efficacy and safety of valsartan and combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension - the VICTORY trial}, keyword = {arterial hypertension, fixed-dose combination, valsartan} }

Časopis indeksira:


  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus


Uključenost u ostale bibliografske baze podataka::


  • EMBASE (Excerpta Medica)
  • MEDLINE
  • Scopus
  • Index Copernicus
  • EBSCO
  • Cros Ref


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font